Loading...
XTAE
BIOV
Market cap6mUSD
Dec 03, Last price  
16.00ILS
1D
0.00%
1Q
-21.95%
Jan 2017
-100.00%
IPO
-100.00%
Name

Bio-View Ltd

Chart & Performance

D1W1MN
XTAE:BIOV chart
P/E
P/S
0.81
EPS
Div Yield, %
Shrs. gr., 5y
57.75%
Rev. gr., 5y
-6.44%
Revenues
26m
-26.21%
25,318,00026,169,00026,047,00023,026,00030,242,00034,534,00033,289,00027,760,00025,280,00035,790,00025,960,00030,513,00029,145,00034,767,00025,655,000
Net income
-3m
L
5,236,0006,576,0001,442,000-1,076,0002,108,0004,066,0004,437,000-1,252,000-1,854,0002,525,000884,0002,184,000587,000383,000-3,148,000
CFO
-3m
L
3,276,0002,350,000-2,916,0003,277,0004,662,0003,727,00054,000-1,325,0002,496,000802,0003,247,000968,000153,000-3,106,000
Dividend
Mar 22, 20172 ILS/sh

Notes

No notes on this company yet
Write a private note on this company, for your eyes only

Profile

Bio-View Ltd develops, manufactures, and markets automated cell imaging and analysis solutions for use in cytology, cytogenetic, and pathology clinical and research laboratories in Israel and internationally. Its products include Accord, a workbench microscope station for semi-automated fluorescent imaging and analysis; Accord Plus, an automatic fluorescent imaging system that automatically scans, analyses, and sorts a range of FISH samples in real-time; and Allegro Plus, an automatic fluorescent imaging system, which identifies various chromosomal aberrations under fluorescent light, such as amplifications, translocations, inversions, and deletions. It also offers DUET-3, an imaging and analysis platform that include an automated barcode reader, which enables scanning of various test types in a single scan batch; DeNovo, an automated scanning system for detection, analysis, and characterization of circulating tumor cells from peripheral blood; Solo Workstation, an offline workstation that streamlines and enables review and analysis of test results away from the microscope; Solo Touch Workstation, a stand-alone workstation with advanced review and analysis tools; and SoloWeb, a Web-based solution that provides analysis, reporting, and consulting on BioView-scanned cases. Bio-View Ltd has a partnership agreement with ANGLE plc to develop a liquid biopsy circulating tumor cell HER2 assay for breast cancer. The company was founded in 2000 and is headquartered in Rehovot, Israel.
IPO date
Mar 07, 2006
Employees
34
Domiciled in
IL
Incorporated in
IL

Valuation

Title
ILS in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2024‑122023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑12
Income
Revenues
Cost of revenue
Unusual Expense (Income)
NOPBT
NOPBT Margin
Operating Taxes
Tax Rate
NOPAT
Net income
Dividends
Dividend yield
Proceeds from repurchase of equity
BB yield
Debt
Debt current
Long-term debt
Deferred revenue
Other long-term liabilities
Net debt
Cash flow
Cash from operating activities
CAPEX
Cash from investing activities
Cash from financing activities
FCF
Balance
Cash
Long term investments
Excess cash
Stockholders' equity
Invested Capital
ROIC
ROCE
EV
Common stock shares outstanding
Price
Market cap
EV
EBITDA
EV/EBITDA
Interest
Interest/NOPBT